TGF-β3 has been suggested to be therapeutic in a mouse model of SLE[25], and the findings of this study suggest that TGF-β3 modifying therapy may be therapeutic in human autoimmune diseases with B cell dysregulation. The gene discussed is TGFB3; the disease is systemic lupus erythematosus.